After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.

Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult ...

Investing.com -- Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm slashed its price target for the stock to $180 from $250 ...

In parallel, Biogen’s research strategy is transforming to revitalize drug discovery and ensure the company remains at the forefront of scientific innovation in its new areas of interest.

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

We're maintaining our $340 fair value estimate for Biogen following in-line performance in the fourth quarter of 2022 and guidance for 2023 that ... New Biogen CEO Positioned to Rework Pipeline ...

Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pipeline re-prioritization underway while signaling that the formerly restrained company is ready to make some deals. “I ...

Biogen CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances the company's characteristic risky bets with a frank commitment to pragmatism.

The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company ...

Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA ...

Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA ...